B7-H4 Targeted Antibody Therapy Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review

Target 1: B7-H4

Product Category: Antibody

This product provides basic pipeline information on investigational antibodies targeting B7-H4.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to La Merie Publishing’s database for investigational antibody therapies targeting B7-H4 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

B7-H4 is a member of the B7 family of immune checkpoint ligands and has been shown to negatively regulate T-cell function. B7-H4 binds to an unknown receptor on T cells and inhibits T-cell proliferation and cytokine production. B7-H4 expression is elevated across a broad range of solid tumors, including ovarian cancer, breast cancer, endometrial carcinoma, cholangiocarcinoma and gallbladder carcinoma, and squamous non-small cell lung cancer tumors. B7-H4 expression is limited in normal tissue, specifically immune cells, making it an ideal molecular target.

A number or antibody modality technologies were used to generate anti-B7-H4 drug candidates undergoing preclinical and clinical development, including antibody-drug conjugates, conditionally activated antibodies, T-cell engaging bispecific antibodies and other effector-enhanced antibody molecules.